MA40623A - Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapie - Google Patents
Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapieInfo
- Publication number
- MA40623A MA40623A MA040623A MA40623A MA40623A MA 40623 A MA40623 A MA 40623A MA 040623 A MA040623 A MA 040623A MA 40623 A MA40623 A MA 40623A MA 40623 A MA40623 A MA 40623A
- Authority
- MA
- Morocco
- Prior art keywords
- elsiglutide
- induced diarrhea
- gastrointestinal mucositis
- including chemotherapy
- treat gastrointestinal
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 title abstract 2
- 229950001278 elsiglutide Drugs 0.000 title abstract 2
- 208000018925 gastrointestinal mucositis Diseases 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048520P | 2014-09-10 | 2014-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40623A true MA40623A (fr) | 2016-03-17 |
Family
ID=54548212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040623A MA40623A (fr) | 2014-09-10 | 2015-09-02 | Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapie |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160067311A1 (enExample) |
| EP (1) | EP3191115A1 (enExample) |
| JP (1) | JP2017532308A (enExample) |
| KR (1) | KR20170052661A (enExample) |
| CN (1) | CN107073081A (enExample) |
| AR (1) | AR103119A1 (enExample) |
| AU (1) | AU2015313919A1 (enExample) |
| BR (1) | BR112017004577A2 (enExample) |
| CA (1) | CA2959110A1 (enExample) |
| CL (1) | CL2017000563A1 (enExample) |
| EA (1) | EA201790552A1 (enExample) |
| IL (1) | IL250928A0 (enExample) |
| MA (1) | MA40623A (enExample) |
| MX (1) | MX2017003166A (enExample) |
| PH (1) | PH12017500426A1 (enExample) |
| SG (1) | SG11201701690WA (enExample) |
| TW (1) | TW201613634A (enExample) |
| WO (1) | WO2016038455A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170087216A1 (en) * | 2015-09-17 | 2017-03-30 | Helsinn Healthcare Sa | Therapeutic Uses of Elsiglutide |
| US11389424B2 (en) | 2017-03-09 | 2022-07-19 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating chemotherapy-induced diarrhea |
| EP4424362A3 (en) * | 2017-06-16 | 2024-11-27 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| BR112022025741A2 (pt) * | 2020-06-19 | 2023-01-03 | Napo Pharmaceuticals Inc | Usos de composições compreendendo crofelemer para tratamento de diarreia induzida por quimioterapia (cid) |
| CN115054683B (zh) * | 2022-05-19 | 2023-06-09 | 唐颢 | 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200709027B (en) * | 2005-04-22 | 2009-01-28 | Novacea Inc | Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof |
| CN101171262B (zh) * | 2005-05-04 | 2012-06-27 | 西兰制药公司 | 胰高血糖素样肽-2(glp-2)类似物 |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
-
2015
- 2015-09-01 US US14/842,250 patent/US20160067311A1/en not_active Abandoned
- 2015-09-02 AU AU2015313919A patent/AU2015313919A1/en not_active Abandoned
- 2015-09-02 EP EP15795220.1A patent/EP3191115A1/en not_active Withdrawn
- 2015-09-02 EA EA201790552A patent/EA201790552A1/ru unknown
- 2015-09-02 MA MA040623A patent/MA40623A/fr unknown
- 2015-09-02 BR BR112017004577A patent/BR112017004577A2/pt not_active Application Discontinuation
- 2015-09-02 CN CN201580060760.4A patent/CN107073081A/zh active Pending
- 2015-09-02 MX MX2017003166A patent/MX2017003166A/es unknown
- 2015-09-02 CA CA2959110A patent/CA2959110A1/en not_active Abandoned
- 2015-09-02 SG SG11201701690WA patent/SG11201701690WA/en unknown
- 2015-09-02 KR KR1020177009656A patent/KR20170052661A/ko not_active Withdrawn
- 2015-09-02 JP JP2017513522A patent/JP2017532308A/ja active Pending
- 2015-09-02 WO PCT/IB2015/001922 patent/WO2016038455A1/en not_active Ceased
- 2015-09-04 TW TW104129362A patent/TW201613634A/zh unknown
- 2015-09-09 AR ARP150102872A patent/AR103119A1/es unknown
-
2017
- 2017-03-05 IL IL250928A patent/IL250928A0/en unknown
- 2017-03-07 PH PH12017500426A patent/PH12017500426A1/en unknown
- 2017-03-08 CL CL2017000563A patent/CL2017000563A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016038455A1 (en) | 2016-03-17 |
| CA2959110A1 (en) | 2016-03-17 |
| TW201613634A (en) | 2016-04-16 |
| CL2017000563A1 (es) | 2017-09-29 |
| EA201790552A1 (ru) | 2017-08-31 |
| US20160067311A1 (en) | 2016-03-10 |
| PH12017500426A1 (en) | 2017-07-31 |
| EP3191115A1 (en) | 2017-07-19 |
| BR112017004577A2 (pt) | 2018-01-23 |
| SG11201701690WA (en) | 2017-04-27 |
| IL250928A0 (en) | 2017-04-30 |
| JP2017532308A (ja) | 2017-11-02 |
| KR20170052661A (ko) | 2017-05-12 |
| CN107073081A (zh) | 2017-08-18 |
| AU2015313919A1 (en) | 2017-03-16 |
| MX2017003166A (es) | 2017-06-19 |
| AR103119A1 (es) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000077A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2018006239A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2018006398A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2018006399A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016529A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016564A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016525A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016560A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| PH12016501763B1 (en) | Multispecific antibodies | |
| MX2017000363A (es) | Inhibicion de la via de notch. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| PH12017500426A1 (en) | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| MX379126B (es) | Formulación de factor viii. | |
| PH12018500339A1 (en) | Lysobactin for use in the treatment of bovine mastitis | |
| UA114708U (uk) | Тяговий привід електробуса | |
| AU364097S (en) | Transportable accommodation pod called Gunya Pod | |
| IN2014CH00035A (enExample) | ||
| UA99992U (ru) | 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния | |
| AU365961S (en) | Clasp | |
| TN2014000522A1 (fr) | لوح مدرسي بوجهين |